CD36 antibody

CD36 antibodies are monoclonal antibodies designed to target CD36 (also known as platelet glycoprotein 4 or fatty acid translocase), a scavenger receptor and transmembrane glycoprotein that facilitates the cellular uptake of long-chain fatty acids and oxidized low-density lipoproteins (oxLDL). In the tumor microenvironment (TME), CD36 is highly expressed on tumor cells, regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and exhausted cytotoxic CD8+ T cells and natural killer (NK) cells. CD36-mediated lipid uptake drives metabolic reprogramming of immunosuppressive cells and induces lipid-mediated functional exhaustion in effector immune cells. By blocking CD36, these antibodies aim to inhibit fatty acid uptake, thereby restoring the metabolic fitness and antitumor activity of cytotoxic T cells and NK cells, depleting or reprogramming immunosuppressive populations (such as Tregs and M2 macrophages), and suppressing tumor growth and metastasis. CD36 antibodies are being developed as metabolic checkpoint immunotherapies for advanced solid tumors, including hepatocellular carcinoma (HCC), and are being evaluated both as monotherapies and in combination with other immune checkpoint inhibitors.

Other names

anti-CD36 antibodyanti-CD-36 antibodyanti-CD 36 antibodyanti-CD36 mAbanti-CD-36 mAbanti-CD 36 mAbanti-CD36 monoclonal antibodyanti-CD-36 monoclonal antibodyanti-CD 36 monoclonal antibodyCD36-blocking antibodyCD-36-blocking antibodyCD 36-blocking antibodyCD36 monoclonal antibodyCD-36 monoclonal antibodyCD 36 monoclonal antibody